In the 1990s and early 2000s, numerous patients with chronic kidney disease (CKD) were exposed to gadolinium-based contrast agents (GBCAs) for contrast-enhanced magnetic resonance imaging (MRI). At the time, the use of GBCAs was considered a safe alternative to iodinated contrast used with computed tomographic scans because the risk of contrast-induced nephropathy could be avoided. During this period, a small number of patients with CKD developed a debilitating skin condition, initially called nephrogenic fibrosing dermopathy, because the most obvious manifestations were diffuse skin thickening and fibrosis. The condition was occasionally severe enough to involve the heart, lungs, liver, and skeletal muscle and was later renamed nephrogenic systemic fibrosis (NSF). Patients with NSF experienced significant morbidity due to irreversible systemic fibrotic changes and higher mortality than patients without NSF.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Maripuri S, Johansen KL. Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease—Is Zero Good Enough? JAMA Intern Med. 2020;180(2):230–232. doi:10.1001/jamainternmed.2019.5278
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: